Kelly Wilson
Houston, TXNPI 1538255344
Payments from drug & device makers
Across 292 payments — averaging $37.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exeltis, USA Inc.$4K
- Biohaven Pharmaceuticals, Inc.$1K
- AbbVie$1K
- Bausch Health US, LLC$729
- Novo Nordisk$674
- Lupin Inc.$318
- plus $3K from 27 others
What the payments were for
- Consulting fees$5,20048%
- Food & beverage$5,56251%
- Education$1321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exeltis, USA Inc. | 1 | $4,000 |
| Biohaven Pharmaceuticals, Inc. | 8 | $1,335 |
| AbbVie(2 entities) | 67 | $1,020 |
| Bausch Health US, LLC | 40 | $729 |
| Novo Nordisk | 24 | $674 |
| Lupin Inc. | 8 | $318 |
| Myovant Sciences Inc. | 13 | $282 |
| Idorsia Pharmaceuticals US Inc | 23 | $265 |
| Amgen | 3 | $256 |
| Pfizer | 12 | $231 |
| Sumitomo Pharma America, Inc. | 9 | $226 |
| Mayne Pharma Commercial LLC | 15 | $179 |
| Avion Pharmaceuticals | 12 | $166 |
| Astellas Pharma US Inc | 3 | $134 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $114 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $106 |
| Axsome Therapeutics, Inc. | 1 | $104 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $102 |
| Currax Pharmaceuticals LLC | 7 | $100 |
| Myriad Women's Health, Inc. | 2 | $86 |
| Lilly USA, LLC | 4 | $82 |
| Hologic Sales And Service, LLC | 3 | $63 |
| Millicent US Inc | 4 | $56 |
| Therapeuticsmd, Inc. | 3 | $53 |
| Agile Therapeutics, Inc. | 2 | $49 |
| Vertical Pharmaceuticals, LLC | 2 | $33 |
| IBSA Pharma Inc. | 2 | $28 |
| Mycovia Pharmaceuticals, Inc. | 1 | $26 |
| Exact Sciences | 1 | $21 |
| Evofem Biosciences, Inc. | 1 | $16 |
| Eisai Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Scynexis, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PremarinEstrogens, Conjugated | 12 | $5,312 |
| Estradiol | 81 | $4,359 |
| ProgesteroneProgesterone, Micronized | 65 | $2,693 |
| ValacyclovirValacyclovir Hcl | 25 | $1,850 |
| Solifenacin Succinate | 13 | $1,035 |
| Vilazodone Hcl | 11 | $699 |
| Trazodone Hcl | 29 | $376 |
| Spironolactone | 11 | $323 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 18 | $320 |
| Nystatin | 11 | $214 |
| Metformin Hcl ErMetformin Hcl | 11 | $147 |
| Levothyroxine Sodium | 13 | $146 |
| Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet | 12 | $137 |
| Fluconazole | 24 | $94 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPremarin | $231 | $5,31212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Texason file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.